US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

231.99

-3.9500-1.67%

Post-market: 228.20-3.7900-1.63%17:17 EDT

Volume:375.69K

Turnover:87.22M

Market Cap:25.04B

PE:-62.64

High:238.93

Open:234.59

Low:230.23

Close:235.94

Loading ...

Overview Company News Filings

RBC Initiates BeiGene at Outperform With $312 Price Target

MT Newswires Live

BUZZ-BeiGene slides after halting lung cancer drug trial due to futility

BeiGene to Discontinue Potential Lung Cancer Treatment Study

MT Newswires Live

BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

MT Newswires Live

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

Simply Wall St.

BeiGene receives positive CHMP opinion for Tevimbra

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

Q4 2024 Zymeworks Inc Earnings Call

Thomson Reuters StreetEvents

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

Simply Wall St.

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

MT Newswires Live

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

BofA Securities Upgrades BeiGene to Buy, Price Target is $320

MT Newswires Live

Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ONC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":231.99,"timestamp":1746820800000,"preClose":235.94,"halted":0,"volume":375689,"hourTrading":{"tag":"盘后","latestPrice":228.2,"preClose":231.99,"latestTime":"17:17 EDT","volume":56602,"amount":13129613.59,"timestamp":1746825449798},"delay":0,"floatShares":78845302,"shares":107947006,"eps":-3.70325,"marketStatus":"Not Yet Opened","change":-3.95,"latestTime":"05-09 16:00:00 EDT","open":234.59,"high":238.93,"low":230.23,"amount":87215104.33812,"amplitude":0.036874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":235.94,"preHourTrading":{"tag":"盘前","latestPrice":232.7,"preClose":235.94,"latestTime":"09:02 EDT","volume":7106,"amount":1676581.96552,"timestamp":1746795722635},"postHourTrading":{"tag":"盘后","latestPrice":228.2,"preClose":231.99,"latestTime":"17:17 EDT","volume":56602,"amount":13129613.59,"timestamp":1746825449798},"volumeRatio":0.7560077917164717,"impliedVol":0.3961,"impliedVolPercentile":0.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":78845302,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.7560077917164717,"shares":107947006,"dividePrice":0,"high":238.93,"amplitude":0.036874,"preClose":235.94,"low":230.23,"week52Low":141.31,"pbRate":"7.16","psRate":"6.00","week52High":287.88,"institutionHeld":0,"latestPrice":231.99,"eps":-3.70325,"divideRate":0,"volume":375689,"delay":0,"ttmEps":-3.70325,"open":234.59,"prevYearClose":184.71,"prevWeekClose":255.77,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":255.77,"twentyDayClose":208.31,"sixtyDayClose":223.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525801520","title":"RBC Initiates BeiGene at Outperform With $312 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2525801520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525801520?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:37","pubTimestamp":1744022277,"startTime":"0","endTime":"0","summary":"BeiGene (ONC) has an average rating of buy and mean price target of $334.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2524501442","title":"BUZZ-BeiGene slides after halting lung cancer drug trial due to futility","url":"https://stock-news.laohu8.com/highlight/detail?id=2524501442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524501442?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:40","pubTimestamp":1743687608,"startTime":"0","endTime":"0","summary":"BUZZ-BeiGene slides after halting lung cancer drug trial due to futility** U.S.-listed shares of cancer drug developer BeiGene 688235.SS, ONC.O fall 3.2% to $266.03** Co says it is discontinuing development of its experimental lung cancer drug, ociperlimab, in a late-stage trial** Independent data monitoring committee recommended terminating the trial** Study unlikely to meet the main goal of improving overall survival, co says ** As of last close, ONC up ~49% YTD vs. 2.4% decline in the Nasdaq biotechnology index .NBI ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nL3N3QH1BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONC","688235","BK0239"],"gpt_icon":0},{"id":"2524681230","title":"BeiGene to Discontinue Potential Lung Cancer Treatment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524681230","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524681230?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:04","pubTimestamp":1743678265,"startTime":"0","endTime":"0","summary":"BeiGene  said Thursday that it will discontinue the development of ociperlimab for lung cancer after an independent review panel recommended that the trial be stopped because the potential treatment was unlikely to improve survival outcomes.BeiGene said no new safety concerns were identified during the trial.Shares of the company were down 1.7% in recent Thursday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06160","ONC","BK4139"],"gpt_icon":0},{"id":"2524723402","title":"BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524723402","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524723402?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:34","pubTimestamp":1743676440,"startTime":"0","endTime":"0","summary":"BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study.BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival.BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker.However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","BK4139","LU0307460666.USD","BK1588","ONC","06160","BK1583","LU2328871848.SGD","LU1969619763.USD","BK1161","LU0588546209.SGD"],"gpt_icon":0},{"id":"2524343582","title":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2524343582","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524343582?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:00","pubTimestamp":1743674400,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., April 03, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab , an anti-TIGIT antibody, as a potential treatment for lung cancer.\"We evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide,\" said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. \"We thank the investigators, their patients, and support staff whose participation and dedication made this research possible.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-provides-ociperlimab-bgb-a1217-100000979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BGB","ONC","BK4139"],"gpt_icon":0},{"id":"2523486309","title":"BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523486309","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523486309?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:32","pubTimestamp":1743420770,"startTime":"0","endTime":"0","summary":"BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a fi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU2328871848.SGD","06160","BK1588","BK1161","LU1969619763.USD","LU0588546209.SGD","BK1500","LU0307460666.USD","ONC","BK1583"],"gpt_icon":0},{"id":"2523910981","title":"Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2523910981","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523910981?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:08","pubTimestamp":1743419309,"startTime":"0","endTime":"0","summary":"Amid recent market volatility, driven by concerns over new tariffs and economic data, investors are keenly observing stocks that may be undervalued in the current climate. Identifying stocks priced below their estimated fair value can offer potential opportunities for those looking to navigate these uncertain times effectively.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Driven Brands Holdings appears undervalued based on its cash flows, trading at US$17.86, significantly below the estimated fair value of US$35.09. Despite a net loss of US$292.5 million in 2024, the company has reduced losses from the previous year and is forecast to achieve profitability within three years with earnings growth expected to outpace market averages. However, revenue growth projections at 4.8% annually are slower than broader market expectations of 8.3%.Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments across the United States, Ch","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/driven-brands-holdings-among-3-110829120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","LU1861559042.SGD","BK4507","LU0205193047.USD","BK4099","BK4532","IE00B64QTZ34.USD","ZK","IE00BLDYK493.USD","LU0106261612.USD","LU1169590202.USD","LU1861558580.USD","BK4585","BK4588","BK4548","HAE","BK4023","BK4108","BK4524","BHLB","BK4197","BK4211","LU1169589451.USD","LU0012050646.USD","NFG","ROKU","DRVN","LU0205194284.USD","BK4539","BK4137","SEMR","ONC"],"gpt_icon":0},{"id":"2523911154","title":"BeiGene receives positive CHMP opinion for Tevimbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2523911154","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523911154?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:15","pubTimestamp":1743416138,"startTime":"0","endTime":"0","summary":"BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinion-for-tevimbra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinion-for-tevimbra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4139","BK4087","ONC"],"gpt_icon":0},{"id":"2523141809","title":"BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523141809","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523141809?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy. SAN CARLOS, Calif., March 31, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA , in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer .\"The aggressive nature of extensive-stage small cell lung cancer makes it an extremely difficult type of lung cancer to treat, and currently available treatments may not adequately control disease progression,\" said Prof. Silvia Novello, M.D., Ph.D., President Women Against Lung Cancer in Europe  and Head of Me","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-receives-positive-chmp-opinion-100000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU0054578231.USD","BK4161","BK4139","BK4087","ONC","OS","CHMP","LU0053671581.USD","ITT","SSI"],"gpt_icon":0},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXN33.USD","ONC","LPTX","IE00BMPRXQ63.HKD","IE00BMPRXR70.SGD","ORR","CRC","LU0266512127.USD","PFS","BK4505","OS","LENZ","BK4113","BK4139","BK4585","LU0348723411.USD","LU0456854461.SGD","BK4609","BK4195","BK4563","BK4213","BK4211","BK4141","BK4543","BK4588","MSS","BK4097"],"gpt_icon":1},{"id":"2521261046","title":"Exploring 3 High Growth Tech Stocks In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2521261046","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521261046?lang=en_us&edition=fundamental","pubTime":"2025-03-22 01:08","pubTimestamp":1742576894,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 2.8% and over the past 12 months, it is up by 7.6%, with earnings expected to grow by 14% per annum over the next few years. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these market conditions.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beigene/news/exploring-3-high-growth-tech-stocks-in-the-us-market-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","BK4507","BK4108","ROKU","LU1861558580.USD","BK4532","BK4139","BK4585","ONC","LU1861559042.SGD","BK4588","BK4524"],"gpt_icon":0},{"id":"2520077627","title":"EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2520077627","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520077627?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:45","pubTimestamp":1742298344,"startTime":"0","endTime":"0","summary":"On Tuesday, Indaptus Therapeutics, Inc.  announced it advanced toa new expansion arm of its Phase 1b/2 clinical trial of Decoy20.The expansion will evaluate the combination of Decoy20 with BeiGene Ltd's  PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early signs of anti-tumor activity.Initial participants will first receive one week of Decoy20 monotherapy intravenously before starting the combination treatment with Decoy20 + tislelizumab.The first few patients in the combination phase will be enrolled sequentially to monitor safety.After review by the trial's Safety Review Committee, unrestricted enrollment will begin.Participants will receive both treatments for up to one year or until disease progression, unacceptable toxicity, or withdrawal from the study.Jeffrey Meckler, CEO of Indaptus, commented, \"This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergisticall","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-indaptus-therapeutics-starts-phase-114544005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","AEIS","ONC","INDP","LENZ","BK4139","BK4157","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2517675761","title":"Q4 2024 Zymeworks Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2517675761","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517675761?lang=en_us&edition=fundamental","pubTime":"2025-03-07 00:12","pubTimestamp":1741277576,"startTime":"0","endTime":"0","summary":"Leone Patterson; Chief Financial Officer, Chief Business Officer, Executive Vice President; Zymeworks Inc. Kenneth Galbraith; Chairman of the Board, President, Chief Executive Officer; Zymeworks Inc. Stephen Willey; Analyst; Stifel Nicolaus and Company, Incorporated. Thank you, Shrinal, and thank you all for joining us today. We're pleased to be reporting on another successful quarter, marked by the approval of zanidatamab and continued progress on our clinical development strategy. Our R&D Day in December last year was a great opportunity for us to evaluate just how far we've come, not only with the development of our wholly owned pipeline over the past two years, but also the larger impact we have been able to make through our global","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-zymeworks-inc-earnings-161256114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC"],"gpt_icon":0},{"id":"2517928856","title":"FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2517928856","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517928856?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:53","pubTimestamp":1741197206,"startTime":"0","endTime":"0","summary":"BeiGene experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development signalling the company's progress in oncology. This approval was based on favorable results from the RATIONALE-306 trial, demonstrating improved overall survival for patients. Further bolstering investor confidence were BeiGene's improved financial reports, showcasing a rise in revenue to $3.8 billion and a reduced net loss compared to the previous year. Additionally, the company's strategic partnerships, such as the collaboration with BostonGene, contributed positively to its growth narrative. These factors contrasted with broader market trends where major indexes reflected slight wavers amid global trade tensions. Compared to a 3.1% market drop recently, BeiGene's robust returns illustrate its ability to navigate challenges while leveraging key advancements in cancer treatment, showing resilience despi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approval-beigene-nasdaqgs-onc-175326509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC","BK4139"],"gpt_icon":1},{"id":"2517932749","title":"BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2517932749","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517932749?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:57","pubTimestamp":1741114643,"startTime":"0","endTime":"0","summary":"BeiGene ( NASDAQ:ONC ) Full Year 2024 Results Key Financial Results Revenue: US$3.81b (up 55% from FY 2023). Net loss...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beigene/news/beigene-full-year-2024-earnings-revenues-beat-expectations-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2516467468","title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2516467468","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516467468?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:09","pubTimestamp":1741097354,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Tuesday, with The Health Care Select Sector SPDR Fund  marginally higher and the iShares Biotechnology ETF  down 0.6%.Illumina  is now prohibited from exporting gene sequencers to China as the company was added to the country's \"Unreliable Entity List,\" according to a statement from China's Ministry of Commerce. Illumina shares were down more than 4% pre-bell.Wave Life Sciences  stock was nearly 4% higher after the company reported that it swung to Q4 net income as revenue rose during the period.BeiGene  shares were up over 2% after the company said the US Food and Drug Administration approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment of certain adults with unresectable or metastatic esophageal squamous cell carcinoma.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","IBB","ONC","XLV","BK4139","BK4121","BK4534","BK4585","ILMN","BK4548","BK4007","BK4588","WVE","BK4581"],"gpt_icon":0},{"id":"2516689627","title":"BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516689627","media":"MT Newswires Live","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516689627?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:36","pubTimestamp":1741088212,"startTime":"0","endTime":"0","summary":"BeiGene  said Tuesday the US Food and Drug Administration approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment of certain adults with unresectable or metastatic esophageal squamous cell carcinoma.The company said the approval is based on a phase 3 study where Tevimbra combination therapy showed a statistically significant improvement in overall survival.Tevimbra is also approved in the US as monotherapy for some patients with esophageal squamous cell carcinoma and in combination with chemotherapy for the first-line treatment of adults with gastric and gastroesophageal junction cancers, it added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0307460666.USD","BK1588","BK1583","BK1161","LU2328871848.SGD","06160","BK1500","LU0588546209.SGD","ONC","BK4139","LU1969619763.USD"],"gpt_icon":0},{"id":"2516622921","title":"TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622921","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622921?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:00","pubTimestamp":1741086000,"startTime":"0","endTime":"0","summary":"New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemotherapy. SAN MATEO, Calif., March 04, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration  has approved TEVIMBRA , in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma  whose tumors express PD-L1 (≥1).\"The approval of TEVIMBRA in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease,\" said Dr. Nataliya Uboha, Associate Professor, University of Wisconsin, Carbone Cancer Center. \"There is a critical need for effective treatments of ESCC, and TEVIMBRA has been shown to improve outcomes in this patient population","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevimbra-approved-u-first-line-110000996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","L","BK4139","IE00B7SZL793.SGD","ITT","BK4588","AEIS","IE00B66KJ199.SGD","BK4144","IE0031619046.USD","BK4107","BK4585","LU0053666078.USD","LU0054578231.USD","LU0053671581.USD","BK4124","BK4161","ONC","BK4157","TEN","BK4097","IE00B19Z4B17.USD","HSCT"],"gpt_icon":0},{"id":"2516801976","title":"BofA Securities Upgrades BeiGene to Buy, Price Target is $320","url":"https://stock-news.laohu8.com/highlight/detail?id=2516801976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516801976?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:22","pubTimestamp":1741004524,"startTime":"0","endTime":"0","summary":"Onconetix Inc (ONCO) has an average rating of buy and mean price target of $316.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2516680387","title":"Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680387","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680387?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:12","pubTimestamp":1741003926,"startTime":"0","endTime":"0","summary":"Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMR","06160","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-09","current":-64.911375,"percent":0,"low":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"high":-22.805663,"avg":-36.524174,"sd":8.290813,"marketCap":25469016595},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595}],"updateTime":1747011891770}}}